Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01QOB
|
||||
| Former ID |
DNC005840
|
||||
| Drug Name |
4-Butoxy-N-hydroxycarbamoylmethyl-benzamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [527800] | ||
| Formula |
C13H18N2O4
|
||||
| Canonical SMILES |
CCCCOC1=CC=C(C=C1)C(=O)NCC(=O)NO
|
||||
| InChI |
1S/C13H18N2O4/c1-2-3-8-19-11-6-4-10(5-7-11)13(17)14-9-12(16)15-18/h4-7,18H,2-3,8-9H2,1H3,(H,14,17)(H,15,16)
|
||||
| InChIKey |
BFVCLRFRELSADQ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Interstitial collagenase | Target Info | Inhibitor | [527800] | |
| PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
| Plasminogen activating cascade | |||||
| WikiPathways | TGF beta Signaling Pathway | ||||
| Bladder Cancer | |||||
| Activation of Matrix Metalloproteinases | |||||
| Degradation of collagen | |||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
| Oncostatin M Signaling Pathway | |||||
| Prostate Cancer | |||||
| Integrated Breast Cancer Pathway | |||||
| Integrated Cancer pathway | |||||
| Cell surface interactions at the vascular wall | |||||
| Matrix Metalloproteinases | |||||
| References | |||||